Showing 6981-6990 of 10191 results for "".
- Cynosure's SculpSure Receives Expanded FDA Clearance for Lipolysis of the Abdomenhttps://practicaldermatology.com/news/cynosures-sculpsure-receives-expanded-fda-clearance-for-lipolysis-of-the-abdomen/2458914/Cynosure, Inc. has received 510(k) clearance from the FDA to market SculpSure™ for non-invasive lipolysis of the abdomen. In May, the FDA cleared SculpSure for non-invasive lipolysis of the flanks. SculpSure is a safe, clinically proven treatment designed to reduce fat non-invasivel
- LEO Pharma Inc. Announces New Vice President of Saleshttps://practicaldermatology.com/news/leo-pharma-inc-announces-new-vice-president-of-sales/2458915/Mitchell Johnson has joined the LEO U.S. Region as Vice President of Sales. "Mitch is a welcomed addition to our team. He is an energetic sales leader and strategist with proven results in the pharmaceutical industry," stated Barbara Osborne, President & CEO, LEO U.S. Mr. Jo
- SCOTUS Upholds Affordable Care Act in King v. Burwell Ruling; AADA and AMA Issue Statementshttps://practicaldermatology.com/news/scotus-upholds-affordable-care-act-in-king-v-burwell-ruling-aada-and-ama-issue-statements/2458920/In a 6-3 ruling in King v. Burwell, the US Supreme Court upheld tax subsidies for the Affordable Care Act. Steven J. Stack, MD, President of the American Medical Association release a statement on the decision, saying “The American Medical Association (AMA) is relieved that today&rs
- FDA Clears Alevicyn SG Antipruritic Spray Gel from Oculus Innovative Scienceshttps://practicaldermatology.com/news/fda-clears-alevicyn-sg-antipruritic-spray-gel-from-oculus-innovative-sciences/2458933/The FDA granted 510(k) clearance to Oculus Innovative Sciences, Inc. for Alevicyn SG Antipruritic Spray Gel with both prescription and over-the-counter indications. The Alevicyn SGprescription product, using Microcyn(R) Technology, is indicate
- ASDSA Supports FDA Fillers Directivehttps://practicaldermatology.com/news/asdsa-supports-fda-fillers-directive/2458935/A recent FDA directive that soft-tissue filler manufacturers include additional precautions on product labels underscores the importance of patients seeking expert physicians for their treatments, according to the American Society for Dermatologic Surgery Association (ASDSA). The FDA is a
- Chief Academy Convenes in San Antoniohttps://practicaldermatology.com/news/chief-academy-convenes-in-san-antonio/2458938/The 2015 Chief Academy convened this month on the campus of the University of Texas Health Science Center - San Antonio, marking a move for the meeting from its 7-year home in Chicago. Dr. Vineet Mishra, Director of Mohs Surgery and Procedural Dermatology as w
- Skin Cancer Foundation Hosts Young Professionals Partyhttps://practicaldermatology.com/news/skin-cancer-foundation-hosts-young-professionals-party/2458943/The Skin Cancer Foundation hosted its 2015 Young Professionals Party in New York City on Thursday, May 14 at the Press Lounge rooftop bar at the Ink 48 Hotel. The event united more than 300 young professionals from the beauty and medical industries in the fight a
- KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA(TM) (also known as ATX-101) -- First and Only Submental Contouring Injectable Drughttps://practicaldermatology.com/news/kythera-biopharmaceuticals-announces-fda-approval-of-kybellatm-also-known-as-atx-101-first-and-only-submental-contouring-injectable-drug/2458953/KYTHERA Biopharmaceuticals, Inc. (Nasdaq:
- Benzac Acne Solutions Premieres “Insta-Dramedy” Webserieshttps://practicaldermatology.com/news/benzac-acne-solutions-premieres-insta-dramedy-webseries/2458955/Galderma Laboratories, L.P launched its first webisode series, “The Benzacs,” a teen insta-dramedy told through 15-second Instagram videos and more than 80 images and short videos. The webseries features the new over-the-counter (OTC) acne treatment Benzac® Acne Solutions, which c
- Merck's Pembrolizumab Demonstrates Positive Results in Phase III Study for Advanced Melanomahttps://practicaldermatology.com/news/mercks-pembrolizumab-demonstrates-positive-results-in-phase-iii-study-for-advanced-melanoma/2458959/Merck announced results from the randomized, pivotal Phase III study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, pembrolizumab was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR).